Page last updated: 2024-12-11
seryl-histidine
Description
seryl-histidine: both amino acids function together as key catalytic amino acids in the active sites of diverse enzymes as the serine- and thiol-proteases, lipases, and esterases [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Ser-His : A dipeptide formed from L-serine and L-histidine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 7016094 |
| CHEMBL ID | 123541 |
| CHEBI ID | 73651 |
| SCHEMBL ID | 2132240 |
| MeSH ID | M0382654 |
Synonyms (27)
| Synonym |
|---|
| chebi:73651 , |
| CHEMBL123541 |
| SCHEMBL2132240 |
| 67726-09-4 |
| l-histidine, n-l-seryl- |
| serylhistidine |
| l-seryl-l-histidine |
| s-h |
| ser-his |
| l-ser-l-his |
| DTXSID10426797 |
| seryl-histidine |
| l-serinyl-l-histidine |
| s-h dipeptide |
| serinylhistidine |
| serine-histidine dipeptide |
| serine histidine dipeptide |
| sh dipeptide |
| CS-0104926 |
| HY-126488 |
| Q27143822 |
| h-ser-his-oh |
| (s)-2-((s)-2-amino-3-hydroxypropanamido)-3-(1h-imidazol-4-yl)propanoic acid |
| MS-23423 |
| (2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid |
| (2s)-2-[(2s)-2-amino-3-hydroxypropanamido]-3-(1h-imidazol-5-yl)propanoic acid |
| AKOS040733347 |
Roles (1)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.49
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.49 (24.57) | | Research Supply Index | 2.56 (2.92) | | Research Growth Index | 5.06 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |